The present invention provides diagnostic and prognostic methods for predicting the effectiveness of treatment of a cancer patient with a DHODH inhibitor or an antimetabolite. Methods are provided for predicting the sensitivity of tumor cell growth to inhibition by a DHODH inhibitor or an antimetabolite, comprising assessing whether the tumor cell comprises a mutant IDH gene or protein whereby cells that comprise a mutant IDH gene or protein are sensitive to inhibition by DHODH inhibitors and antimetabolites.

Provided is an in vitro method for determining the metabolic status of a lymphoma comprising a step of determining the level of glyceraldehyde-3-phosphate dehydrogenase (GAPDH) expression in lymphoma cells, wherein a low level of GAPDH expression is indicative of oxidative phosphorylation (OXPHOS) status. Also provided is an in vitro method for predicting the responsiveness of a patient afflicted with a lymphoma to a treatment with a metabolic inhibitor selected from the group consisting of mitochondrial metabolic inhibitors and glutamine metabolism inhibitors comprising a step of determining the level of GAPDH expression in lymphoma cells obtained from said patient, wherein a low level of GAPDH expression is predictive of a response to a treatment with a metabolic inhibitor.

Provided is GDH with increased applicability to glucose sensors. A composition contains FADGDH, wherein when 0.1 mL of the composition is added to 2.9 mL of a solution containing 10 mM of trehalose and 1 mmol/L of potassium ferricyanide to give a glucose dehydrogenase activity of 500 U/mL and incubated at 37 C., the decrease in absorbance at 405 nm resulting from reduction of the potassium ferricyanide is less than 20 mAbs per minute.

Disclosed herein is a novel use of HSD3B1 in disease diagnosis. According to embodiments of the present disclosure, the mRNA or protein level of HSD3B1 may serve as an indicator for diagnosing hepatocellular carcinoma. Also disclosed herein are methods for treating hepatocellular carcinoma by use of HSD3B1 inhibitor.

Embodiments of the present invention are directed to a semiconductor device. A non-limiting example of the semiconductor device includes a semiconductor substrate. The semiconductor device also includes a plurality of metal nanopillars formed on the substrate. The semiconductor device also includes an amperometric sensor associated with one of the plurality of nanopillars, wherein the amperometric sensor is selective to an enzyme-active neurotransmitter. The semiconductor device also includes a resistivity sensor associated with a pair of nanopillars, wherein the resistivity sensor is selective to an analyte.

This disclosure relates to methods and kits for determining the presence and/or amount of one or more analytes in a keratinized structure (e.g., hair) sample.

Disclosed herein are methods, devices and kits suitable for high throughput screenings of extracellular pyridine nucleotide levels, such as NAD.sup.+ levels which are suitable for monitoring pyridine nucleotide induced slowdown of not only pathogenesis of multiple systemic diseases but also aging. In particular, assaying methods quantifying extracellular pyridine nucleotide(s), such as NAD.sup.+, in the low micromolar to the low nanomolar range in a sample that may have been subjected to long term storage are disclosed using a two-step enzymatic cycling reaction employing an oxidoreductase such as alcohol dehydrogenase. A modified revised simulated body fluid is also disclosed that is employed as a standard matrix to optimise enzymatic activity, linearity and/or sensitivity of the methods, devices and kits.

This disclosure relates to a screening test method, device, and kit for mucosal carbohydrates and associated conditions including, cancerous and precancerous conditions. Specifically, the method tests abnormal carbohydrates in mucus or body fluid using reagents of galactose oxidase, and Schiff's Reagent. The screening test method, device, and kit provides improved accuracy, and minimizes handling procedures. This disclosure further relates to the use of the device or kit in a medical facility for an initial evaluation for cancerous and precancerous conditions.

This disclosure relates to a screening test method, device, and kit for mucosal carbohydrates and associated conditions including, cancerous and precancerous conditions. Specifically, the method tests abnormal carbohydrates in mucus or body fluid using reagents of galactose oxidase, and Schiff's Reagent. The screening test method, device, and kit provides improved accuracy, and minimizes handling procedures. This disclosure further relates to the use of the device or kit in a healthcare facility for an initial evaluation for cancerous and precancerous conditions.

The present invention provide a method for detecting a test substance utilizing a color development caused by an enzyme reaction, or a color development caused by a specific interaction such as an antigen-antibody reaction and an enzyme reaction, the test substance being detected rapidly, sensitively and quantitatively without using a spectroscopic measurement device. The method for measuring a concentration of a test substance by the present invention comprises the steps of: generating a peroxide from the test substance; obtaining a polymerized substance by bringing an oxidoreductase for producing a polymerized substance and a substrate of the oxidoreductase for producing a polymerized substance into contact with the peroxide; and irradiating the polymerized substance with light to record a temporal variation information of an intensity of scattered light generated from an irradiation point.